An editorial to educate scientific and advocacy communities as well as investors on the scientific strategies and disease areas in Arcus Biosciences' pipeline. The introduction provides background on the different biological components and pathways to potentially treat cancer through immunotherapy, namely TIGIT/PD-1 and adenosine. The main graphic was redesigned from an existing one to align with the style of another story I created animations for. Users can then explore within distinct tabs how these combination therapies can work within each disease area Arcus is researching.
Agency: Weber Shandwick | Client: Arcus Biosciences | Role: Graphic Design, UI Design
